&nbsp;

Drugs Used:

ribociclib ,

fulvestrant

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ABEMLETR

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria

ODB - General Benefit

letrozole

Drugs Used:

abemaciclib,

letrozole

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

ABEMANAS

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

anastrozole

Drugs Used:

abemaciclib,

anastrozole

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

ABEMFLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

abemaciclib (Unfunded),

fulvestrant

Quick Link(s):

Regimen Monograph

Oct 2025

Regimen

CHOP

Cancer Type:

Hematologic,

Rare Diseases,

Sarcoma

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

CRBPETOP(PO)+ATEZ

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Funding:

ODB - General Benefit

etoposide - oral capsules

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut),

CARBOplatin,

etoposide

Quick Link(s):

Regimen Monograph

May 2025

Regimen

EVERLENV

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

ODB - General Benefit

everolimus

Drugs Used:

lenvatinib (Unfunded),

everolimus

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

BORTCYCDOXPRED+R

Cancer Type:

Hematologic

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Bortezomib - Previously Untreated Transplant Ineligible Mantle Cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

LOMU+BEVA

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma

Drugs Used:

lomustine,

bevacizumab

Quick Link(s):

Regimen Monograph

May 2024

Regimen

GDP+OBIN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2020

Regimen

DHAP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

ODB - General Benefit

dexamethasone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used: